Clinical Trial Update: Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 study of rapastinel monotherapy for major depressive disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Rapastinel (Rapastinel)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Depressive Disorder, Major | Phase 3 | Status: WITHDRAWN